Announcements Trials

Browse Landscape

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Pulmonary Atelectasis 1 Postural Orthostatic Tachycardia Syndrome 1 Postoperative Complications 1 Pneumonia 1 Pancreatic carcinoma, familial 1 Pancreatic cancer, adult 1 Neoplasms 1 Multiple Myeloma 1 Mastocytosis 1 Lung Cancer Screening 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Esophageal Neoplasms 1 Bronchopulmonary Disease 1 Barrett Esophagus 1 Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 13 pembrolizumab 12 Paclitaxel 12 Oxaliplatin 12 Leucovorin 9 Carboplatin 9 Capecitabine 8 Trastuzumab 7 Nivolumab 7 Cisplatin 7 Radiotherapy 6 Radiation 6 Taxes 5 Esophagectomy 5 Drug Therapy 5 Surgical Procedures, Operative 4 Specimen Handling 4 Irinotecan 4 trastuzumab deruxtecan 3 tislelizumab 3 patritumab deruxtecan 3 Radiotherapy, Intensity-Modulated 3 Proton Therapy 3 Immunotherapy 3 zanidatamab 2 ulixertinib 2 trastuzumab biosimilar HLX02 2 relatlimab 2 durvalumab 2 atezolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Esophageal Neoplasms × Mass Screening × 90 days × Clear all

NCT06335966 2026-03-17

BEST-RPP

OHSU Knight Cancer Institute

Active not recruiting

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡